A Study on Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)

Rituximab in the Treatment of Chronic Lymphocytic Leukemia, "CLL NIS"

This observational study will assess the therapeutic efficiency, treatment schedules, handling procedures, and the safety profile of rituximab in routine care in participants with CLL.

Inclusion Criteria:

• CLL requiring treatment
• Participants receiving a chemotherapy in combination with rituximab (decision taken by doctor prior to and independent from inclusion in this non-interventional study)
• After this trial started, an amendment to the study protocol was introduced, adding a further inclusion criterion: Comorbidities according to cumulative illness rating scale (CIRS) score greater than (>) 6 and/or creatinine clearance less than (<) 70 milliliters per minute (mL/min)

Exclusion Criteria:

• Participants with contraindication to rituximab treatment